ClinicalTrials.gg
CompletedNCT01407523Updated Mar 7, 2013Results posted

An Open Label Study of L059 Intravenous (IV) in Japanese Epilepsy Subjects With Partial Onset Seizures

A Phase 2 interventional study of Levetiracetam in Epilepsy and Partial Onset Seizures, sponsored by UCB Japan Co. Ltd.. Completed at 4 sites in Japan. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2013-03-07.

Sponsored by UCB Japan Co. Ltd. (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing levetiracetam in Epilepsy — 4 open to participants now, 4 under way, 2 of them phase 3. Levetiracetam · Epilepsy.

Enrollment
51st of 60
16 · median 94
Started
2011
with 4 others
Phase 2
11 of 60
none open now
Registered
43rd of 60
by date
Lead sponsor
7 of 60
UCB Japan Co. Ltd.

Among the 60 studies testing levetiracetam in Epilepsy, this one is the 51st largest by enrollment, is one of 5 that started in 2011, is one of 11 in phase 2, and was the 43rd registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

4 of the 60 studies testing levetiracetam in Epilepsy are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About levetiracetam

Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing levetiracetam in Epilepsy, or all of them as a file.
02

Study summary

To evaluate the safety of Levetiracetam IV 15-minute infusion administered every 12 hours as adjunctive treatment in subjects with Partial Onset Seizures after switching from the equivalent Levetiracetam oral dose.

03

Conditions studied

  • Epilepsy
  • Partial Onset Seizures

Browse trials for

Keywords

  • Levetiracetam
  • Infusion
  • Epilepsy
  • Partial Onset Seizures
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is a male or female aged ≥ 16 years
  • Subject has Partial Onset Seizures that are classifiable according to the 1981 International League Against Epilepsy (ILAE) classification of Epileptic Seizures
  • Subject weighs ≥ 40 kg
  • Subject is currently taking Levetiracetam (LEV) as an adjunctive antiepileptic oral treatment with 1 to 3 other Antiepileptic Drugs (AEDs)

Exclusion criteria

Exclusion Criteria:

  • Subject has problems with venous accessibility
  • Subject has participated in another clinical/pharmacological study during the last 4 weeks prior to the Screening Visit
  • Subject is pregnant or lactating
  • Subject has a history of suicide attempt(s) or presents with current depressive signs, current suicidal ideation, and/or behavior
  • Subject has (ECG) abnormalities according to the investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Levetiracetam

    Twice daily intravenous (IV) infusion of Levetiracetam solution equivalent (mg-for-mg) to oral dose of Levetiracetam.

    Drug: Levetiracetam

Interventions

  • * Formulation: concentrate for solution for infusion * Strength: Levetiracetam injection (100 mg/mL) will be packed in 5 mL glass vials (500 mg/5 mL) * Dosage: 1000 mg/day, 1500 mg/day, 2000 mg/day, 2500 mg/day or 3000 mg/day * Frequency: twice daily

    Also known as: Keppra®, E Keppra®

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment Emergent Adverse Events During the Entire Study Period (up to 32 Days)

    An Adverse Event (AE) is any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: During the entire Study Period from Screening (Day -14 to Day -1) over Evaluation Period (Day 1 to Day 4) to Follow-Up Period (Day 5 to Day 18)

  2. Incidence of Treatment Emergent Serious Adverse Events During the Entire Study Period (up to 32 Days)

    A Serious Adverse Event (SAE) is any untoward medical occurrence that results in death, is life-threatening, results in significant or persistent disability/incapacity, is a congenital anomaly/birth defect (including that occurring in a fetus), or is an important medical event that may jeopardize the subject or may require medical or surgical intervention.

    Time frame: During the entire Study Period from Screening (Day -14 to Day -1) over Evaluation Period (Day 1 to Day 4) to Follow-Up Period (Day 5 to Day 18)

Secondary outcomes

  1. Observed Plasma Trough Concentration of Levetiracetam Prior to Intravenous (iv) Infusion on Day 1

    Plasma sample for determination of Plasma trough concentration of Levetiracetam was taken prior to intravenous infusion of Levetiracetam in the morning of Day 1.

    Time frame: Day 1

  2. Observed Plasma Trough Concentration of Levetiracetam Prior to Intravenous (iv) Infusion on Day 4

    Plasma sample for determination of Plasma trough concentration of Levetiracetam was taken prior to intravenous infusion of Levetiracetam in the morning of Day 4.

    Time frame: Day 4

  3. Dose Normalized Plasma Trough Concentration of Levetiracetam Prior to Intravenous (iv) Infusion on Day 1

    Plasma sample for determination of Plasma trough concentration of Levetiracetam was taken prior to intravenous infusion of Levetiracetam in the morning of Day 1. Plasma trough concentration (Ctrough) was normalized to a dose of 500 mg as follows: Dose normalized Ctrough = Ctrough/last dose \[mg\] x 500 mg.

    Time frame: Day 1

  4. Dose Normalized Plasma Trough Concentration of Levetiracetam Prior to Intravenous (iv) Infusion on Day 4

    Plasma sample for determination of Plasma trough concentration of Levetiracetam was taken prior to intravenous infusion of Levetiracetam in the morning of Day 4. Plasma trough concentration (Ctrough) was normalized to a dose of 500 mg as follows: Dose normalized Ctrough = Ctrough/last dose \[mg\] x 500 mg.

    Time frame: Day 4

  5. Partial (Type 1) Seizure Frequency Per Day Over the Evaluation Period

    Partial (Type I) seizures can be classified into one of the following three groups: Simple partial seizures, Complex partial seizures, Partial seizures evolving to secondarily generalized seizures.

    Time frame: During the Evaluation Period (Day 1 to Day 4)

07

Results

Posted Mar 7, 2013

Participant flow

This study started to enroll subjects in July 2011 in order to end up with 4 centers in Japan. 16 subjects were treated and completed the study. All 16 subjects are included in the Safety Set.

Participant flow — Overall Study
MilestoneLevetiracetam
Started16
Completed16
Not completed0

Outcome measures

PrimaryIncidence of Treatment Emergent Adverse Events During the Entire Study Period (up to 32 Days)

An Adverse Event (AE) is any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

Time frame:
During the entire Study Period from Screening (Day -14 to Day -1) over Evaluation Period (Day 1 to Day 4) to Follow-Up Period (Day 5 to Day 18)
Reported as:
Number · participants
Incidence of Treatment Emergent Adverse Events During the Entire Study Period (up to 32 Days)
participantsLevetiracetam
Incidence of Treatment Emergent Adverse Events During the Entire Study Period (up to 32 Days)5
PrimaryIncidence of Treatment Emergent Serious Adverse Events During the Entire Study Period (up to 32 Days)

A Serious Adverse Event (SAE) is any untoward medical occurrence that results in death, is life-threatening, results in significant or persistent disability/incapacity, is a congenital anomaly/birth defect (including that occurring in a fetus), or is an important medical event that may jeopardize the subject or may require medical or surgical intervention.

Time frame:
During the entire Study Period from Screening (Day -14 to Day -1) over Evaluation Period (Day 1 to Day 4) to Follow-Up Period (Day 5 to Day 18)
Reported as:
Number · participants
Incidence of Treatment Emergent Serious Adverse Events During the Entire Study Period (up to 32 Days)
participantsLevetiracetam
Incidence of Treatment Emergent Serious Adverse Events During the Entire Study Period (up to 32 Days)0
SecondaryObserved Plasma Trough Concentration of Levetiracetam Prior to Intravenous (iv) Infusion on Day 1

Plasma sample for determination of Plasma trough concentration of Levetiracetam was taken prior to intravenous infusion of Levetiracetam in the morning of Day 1.

Time frame:
Day 1
Reported as:
Geometric mean · micrograms per milliliter (µg/mL)
Observed Plasma Trough Concentration of Levetiracetam Prior to Intravenous (iv) Infusion on Day 1
micrograms per milliliter (µg/mL)Levetiracetam
Observed Plasma Trough Concentration of Levetiracetam Prior to Intravenous (iv) Infusion on Day 111.732 ± 63.1
SecondaryObserved Plasma Trough Concentration of Levetiracetam Prior to Intravenous (iv) Infusion on Day 4

Plasma sample for determination of Plasma trough concentration of Levetiracetam was taken prior to intravenous infusion of Levetiracetam in the morning of Day 4.

Time frame:
Day 4
Reported as:
Geometric mean · micrograms per milliliter (µg/mL)
Observed Plasma Trough Concentration of Levetiracetam Prior to Intravenous (iv) Infusion on Day 4
micrograms per milliliter (µg/mL)Levetiracetam
Observed Plasma Trough Concentration of Levetiracetam Prior to Intravenous (iv) Infusion on Day 411.632 ± 59.6
SecondaryDose Normalized Plasma Trough Concentration of Levetiracetam Prior to Intravenous (iv) Infusion on Day 1

Plasma sample for determination of Plasma trough concentration of Levetiracetam was taken prior to intravenous infusion of Levetiracetam in the morning of Day 1. Plasma trough concentration (Ctrough) was normalized to a dose of 500 mg as follows: Dose normalized Ctrough = Ctrough/last dose \[mg\] x 500 mg.

Time frame:
Day 1
Reported as:
Geometric mean · micrograms per milliliter (µg/mL)
Dose Normalized Plasma Trough Concentration of Levetiracetam Prior to Intravenous (iv) Infusion on Day 1
micrograms per milliliter (µg/mL)Levetiracetam
Dose Normalized Plasma Trough Concentration of Levetiracetam Prior to Intravenous (iv) Infusion on Day 16.611 ± 29.6
SecondaryDose Normalized Plasma Trough Concentration of Levetiracetam Prior to Intravenous (iv) Infusion on Day 4

Plasma sample for determination of Plasma trough concentration of Levetiracetam was taken prior to intravenous infusion of Levetiracetam in the morning of Day 4. Plasma trough concentration (Ctrough) was normalized to a dose of 500 mg as follows: Dose normalized Ctrough = Ctrough/last dose \[mg\] x 500 mg.

Time frame:
Day 4
Reported as:
Geometric mean · micrograms per milliliter (µg/mL)
Dose Normalized Plasma Trough Concentration of Levetiracetam Prior to Intravenous (iv) Infusion on Day 4
micrograms per milliliter (µg/mL)Levetiracetam
Dose Normalized Plasma Trough Concentration of Levetiracetam Prior to Intravenous (iv) Infusion on Day 45.492 ± 29.4
SecondaryPartial (Type 1) Seizure Frequency Per Day Over the Evaluation Period

Partial (Type I) seizures can be classified into one of the following three groups: Simple partial seizures, Complex partial seizures, Partial seizures evolving to secondarily generalized seizures.

Time frame:
During the Evaluation Period (Day 1 to Day 4)
Reported as:
Median · Seizures per day
Partial (Type 1) Seizure Frequency Per Day Over the Evaluation Period
Seizures per dayLevetiracetam
Partial (Type 1) Seizure Frequency Per Day Over the Evaluation Period0.38 (0.00 to 1.00)

Adverse events

Collected over Adverse Events (AEs) were collected over the entire Study Period from Screening (1 to 14 days prior to the first intravenous infusion) over Evaluation Period (4 days) to the end of Follow-Up Period (1 to 14 days after the final intravenous infusion).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Levetiracetam—0/16 (0%)5/16 (31.3%)
Most frequent other events
Most frequent other events
EventLevetiracetam
GingivitisGastrointestinal disorders1/16
ToothacheGastrointestinal disorders1/16
Injection site inflammationGeneral disorders1/16
Injection site painGeneral disorders1/16
Injection site swellingGeneral disorders1/16
ContusionInjury, poisoning and procedural complications1/16
ArthralgiaMusculoskeletal and connective tissue disorders1/16

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Levetiracetam
<=18 years0
Between 18 and 65 years16
>=65 years0
Age Continuous
Age Continuous(years)Levetiracetam
Mean32.9 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)Levetiracetam
Female8
Male8
Region of Enrollment
Region of Enrollment(participants)Levetiracetam
Japan16
Weight
Weight(kilogram)Levetiracetam
Mean68.82 ± 12.38
Height
Height(centimeter)Levetiracetam
Mean163.40 ± 8.95
08

Study locations

4 sites
  • 1
    Niigata-city, Niigata, Japan
  • 2
    Shizuoka-city, Shizuoka, Japan
  • 3
    Kodaira-city, Tokyo, Japan
  • 4
    Yamagata-city, Yamagata, Japan
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2013, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2011
First posted
Aug 2, 2011
Start
Jul 2011
Primary completionActual
Feb 2012
CompletionActual
Feb 2012
Results first posted
Mar 7, 2013
Last update
Mar 7, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01407523
Lead sponsor
UCB Japan Co. Ltd.
Responsible party
Sponsor
First posted
Aug 2, 2011
Start date
Jul 2011
Primary completion
Feb 2012
Completion
Feb 2012
Results posted
Mar 7, 2013
Last update
Mar 7, 2013

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion